Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02602938
Other study ID # 2015KY163
Secondary ID
Status Recruiting
Phase Phase 2
First received November 9, 2015
Last updated November 12, 2015
Start date November 2015
Est. completion date February 2017

Study information

Verified date November 2015
Source Zhejiang Provincial People’s Hospital
Contact Chao Ni, Doctor
Phone +8613989463951
Email davenc@163.com
Is FDA regulated No
Health authority China: Ethics committee of Zhejiang Provincial people's hospital
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether Aspirin could affect the number and subtype of circulating tumor cells of metastatic breast cancer and colorectal cancer.


Description:

BACKGROUND:

- Invasion and metastasis are the main reason of death in metastatic cancer, and abundant evidence find circulating tumor cells(CTCs) take the core position in breast and colorectal cancer metastasis.

- Platelets play multiple role to facilitate the epithelial to mesenchymal transition of tumor cells and protect CTCs to survival in the circulation, which enrolled in the whole process of metastasis.

- Several clinical trials and observational study have validate the primary and secondary prevention effect of aspirin to both breast and colorectal cancer.

OBJECTIVES:

- Determine the effect of aspirin on CTC number of metastatic breast and colorectal cancer;

- Determine the effect of aspirin on CTC subtype (epithelial/mesenchymal/mixed type) of metastatic breast and colorectal cancer.

ELIGIBILITY:

- Adults age from 18-75 years old.

- Patients were diagnosed for metastatic breast or colorectal cancer by pathology.

- Patients who were not currently receiving intravenous chemotherapy , oral administrated with capecitabine was permitted. Concurrent endocrine therapy ( for at least 2 months before enrollment), bisphosphonate therapy, and/or monoclonal targeted therapy were permitted.

- No disease of hemorrhagic tendency or history of non-steroid drug allergy.

- CTCs≥5 / 7.5ml blood

STUDY DESIGN:

- Aspirin will be administered orally once a day in 28-day cycles.

- The CTC was evaluated every 28 days for 2 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date February 2017
Est. primary completion date November 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Adults age from 18-75 years old.

- Patients were diagnosed for metastatic breast or colorectal cancer by pathology.

- Patients who were not currently receiving intravenous chemotherapy , oral administrated with capecitabine was permitted.

- Concurrent endocrine therapy ( for at least 2 months before enrollment), bisphosphonate therapy, and/or monoclonal targeted therapy were permitted.

- PS score = 3

- Anticipated survival time = 3 months

- CTCs=5 / 7.5ml blood

Exclusion Criteria:

- Allergic to aspirin or other types of non-steroid

- History of hemorrhage of digestive tract or other hemorrhagic disease

- Plan to receive surgery within the time frame of the trial

- Medication history of aspirin or other types of anti-platelets drug within one months before the trial

- Women in pregnant or lactation period

- Any psychological or objective problem may influence the compliance of the patients

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
Aspirin
Take aspirin (100mg) orally once a day for 2 months

Locations

Country Name City State
China Zhejiang provincial people's hospital Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang Provincial People’s Hospital

Country where clinical trial is conducted

China, 

References & Publications (3)

Ksiazkiewicz M, Markiewicz A, Zaczek AJ. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology. 2012;79(4):195-208. doi: 10.1159/000337106. Epub 2012 Apr 4. Review. — View Citation

Maity G, De A, Das A, Banerjee S, Sarkar S, Banerjee SK. Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition. Lab Invest. 2015 Jul;95(7):702-17. doi: 10.1038/labinvest.2015.49. Epub 2015 Apr 13. — View Citation

Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012 Apr 28;379(9826):1591-601. doi: 10.1016/S0140-6736(12)60209-8. Epub 2012 Mar 21. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Intervention completed 2-months follow-up completed and the CTCs' assessment was evaluated three times by Canpatrol technology, the tumor burden was evaluated by MRI or CT. 2 months Yes
Secondary Disease progression The tumor burden would be examined by MRI or CT once a month, if we find the cancer progressed and chemotherapy is needed, the patient will be withdraw. 2 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT02072616 - Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. Phase 3
Completed NCT02808884 - Cancer DNA Screening Pilot Study (CANDACE) N/A
Recruiting NCT06068348 - Liquid Biopsy Collection Study
Completed NCT02335151 - CTC Pancreatic Adenocarcinoma Phase 4
Completed NCT01015625 - Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer N/A
Completed NCT02499458 - Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer
Completed NCT03101046 - Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic Phase 2
Completed NCT02449837 - Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy
Recruiting NCT02451384 - According CTC to Compare the Influences of Different Methods to Remove the PDAC N/A
Recruiting NCT01052818 - Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer N/A
Not yet recruiting NCT04239105 - Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device
Recruiting NCT03156777 - Application Value of CTCs Detection for Advanced Gastric Cancer Patients N/A
Recruiting NCT02554448 - Detection of CTCs in Stage III Rectal Cancer Patients Undergoing Neoadjuvant Therapy N/A
Completed NCT02345473 - Detection and Clinical Significance of Circulating Cancer Cells in Patient Undergoing Radical Cystectomy N/A
Not yet recruiting NCT04229121 - Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
Completed NCT02955173 - Significance of Circulating Tumor Cells in the Treatment of Gastric and Rectal Cancer N/A
Completed NCT03340844 - Role of CTC´s Spread During Pancreaticoduodenectomy in Patients With Pancreatic and Periampullary Tumors N/A
Active, not recruiting NCT03381326 - CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.
Completed NCT05502458 - Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor Phase 2
Enrolling by invitation NCT04972461 - Therapeutic Response Evaluation by CTC Expansion System